{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:21:45Z","timestamp":1770960105049,"version":"3.50.1"},"reference-count":27,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s564116","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:30:25Z","timestamp":1767169825000},"page":"3383-3392","source":"Crossref","is-referenced-by-count":1,"title":["Rhabdomyolysis as a Predominant Multisystem Serious Immune-Related Adverse Event Induced by Sintilimab: A Case Report and Literature Review"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Qingyuan","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2388-7597","authenticated-orcid":true,"given":"Minjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"Postow","year":"2018","journal-title":"New England J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","volume":"81","author":"Nguy\u1ec5n","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","volume":"20","author":"O\u2019Hare","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1053370","DOI":"10.3389\/fonc.2022.1053370","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0306995","DOI":"10.1371\/journal.pone.0306995","volume":"19","author":"Sumimoto","year":"2024","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12032-020-01357-x","volume":"37","author":"Ida","year":"2020","journal-title":"Med Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CJI.0000000000000299","volume":"43","author":"Suzuki","year":"2020","journal-title":"Journal of Immunotherapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.21873\/anticanres.11814","volume":"37","author":"Ariyasu","year":"2017","journal-title":"Anticancer Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3174\/ajnr.A1623","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2020.0032","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"Muir","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16405","author":"Chen","year":"2024","journal-title":"Br J Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1161768","DOI":"10.3389\/fendo.2023.1161768","volume":"14","author":"Khadka","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref27","unstructured":"In conclusion, this case report describes a 55-year-old female lung cancer patient who developed severe multisystem irAEs, dominated by rhabdomyolysis, following sintilimab treatment. Her rapid and significant clinical improvement, observed as early as the third day of high-dose corticosteroid pulse therapy, underscores the potential efficacy of corticosteroids in managing such life-threatening irAEs, even in complex presentations. This outcome reinforces that corticosteroids remain a critical, accessible, and cost-effective option in the therapeutic arsenal against severe irAEs. However, their use should be balanced against potential adverse effects. Importantly, this single case experience highlights the necessity for vigilant, multisystem monitoring and early differential diagnosis to ensure timely intervention. Future studies are needed to validate these findings and optimize management strategies across broader patient populations."}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/110595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/110595","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:30:32Z","timestamp":1767169832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/rhabdomyolysis-as-a-predominant-multisystem-serious-immune-related-adv-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2147\/cmar.s564116","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}